Mary Ann Jabra-Rizk

List of Publications by Year
in descending order

64 papers	5,566 citations	101496 36 h-index	118793 62 g-index
65 all docs	65 docs citations	65 times ranked	6925 citing authors

#	Article	IF	Citations
1	Application of proper orthogonal decomposition for evaluation of coherent structures and energy contents in microbial biofilms. Journal of Microbiological Methods, 2022, 194, 106420.	0.7	1
2	Long-Term Post-COVID-19 Associated Oral Inflammatory Sequelae. Frontiers in Cellular and Infection Microbiology, 2022, 12, 831744.	1.8	5
3	The Global Emergence of the Fungal Pathogen Candida auris. Clinical Infectious Diseases, 2021, 72, 178-179.	2.9	1
4	Salivary biomarker profiles in Eâ€cigarette users and conventional smokers: A crossâ€sectional study. Oral Diseases, 2021, 27, 277-279.	1.5	5
5	Therapeutic implications of <i>C. albicans-S. aureus</i> mixed biofilm in a murine subcutaneous catheter model of polymicrobial infection. Virulence, 2021, 12, 835-851.	1.8	37
6	Editorial overview of Pearls Microbiome Series: E pluribus unum. PLoS Pathogens, 2021, 17, e1009912.	2.1	0
7	PROLONGED FACIAL MASK WEAR IS A CONCERN FOR THE DEVELOPMENT OF DYSBIOTIC MICROBIOME. Respiratory Medicine and Research, 2021, 81, 100877.	0.4	2
8	Convalescent serum therapy for COVID-19:ÂA 19th century remedy for a 21st century disease. PLoS Pathogens, 2020, 16, e1008735.	2.1	23
9	Comparative Evaluations of the Pathogenesis of Candida auris Phenotypes and Candida albicans Using Clinically Relevant Murine Models of Infections. MSphere, 2020, 5, .	1.3	19
10	The Role of Candida albicans Secreted Polysaccharides in Augmenting Streptococcus mutans Adherence and Mixed Biofilm Formation: In vitro and in vivo Studies. Frontiers in Microbiology, 2020, 11, 307.	1.5	49
11	<i>Candida auris:</i>a fungus with identity crisis. Pathogens and Disease, 2020, 78, .	0.8	18
12	Oral Candidiasis: A Disease of Opportunity. Journal of Fungi (Basel, Switzerland), 2020, 6, 15.	1.5	200
13	Adhesion of Staphylococcus aureus to Candida albicans During Co-Infection Promotes Bacterial Dissemination Through the Host Immune Response. Frontiers in Cellular and Infection Microbiology, 2020, 10, 624839.	1.8	25
14	Evaluation of the Antifungal and Wound-Healing Properties of a Novel Peptide-Based Bioadhesive Hydrogel Formulation. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
15	<i>Candida albicans</i> quorum-sensing molecule farnesol modulates staphyloxanthin production and activates the thiol-based oxidative-stress response in <i>Staphylococcus aureus</i>. Virulence, 2019, 10, 625-642.	1.8	35
16	The power of saliva: Antimicrobial and beyond. PLoS Pathogens, 2019, 15, e1008058.	2.1	65
17	Digital Design of a Universal Rat Intraoral Device for Therapeutic Evaluation of a Topical Formulation against <i>Candida</i> -Associated Denture Stomatitis. Infection and Immunity, 2019, 87, .	1.0	15
18	Candidalysin Crucially Contributes to Nlrp3 Inflammasome Activation by Candida albicans Hyphae. MBio, 2019, 10, .	1.8	70

#	Article	IF	Citations
19	Topical therapy for refractory rhinosinusitis caused by methicillin-resistant Staphylococcus aureus : First report in a prospective series. Auris Nasus Larynx, 2018, 45, 994-999.	0.5	4
20	Engineering improved variants of the antifungal peptide histatin 5 with reduced susceptibility to <i>Candida albicans</i> secreted aspartic proteases and enhanced antimicrobial potency. FEBS Journal, 2018, 285, 146-159.	2.2	24
21	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	1.4	81
22	The oral microbiome: A Lesson in coexistence. PLoS Pathogens, 2018, 14, e1006719.	2.1	80
23	Fungalâ€"Bacterial Interactions: In Health and Disease. , 2017, , 115-143.		5
24	Modulation of Staphylococcus aureus Response to Antimicrobials by the Candida albicans Quorum Sensing Molecule Farnesol. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	73
25	Farnesol and <i>Candida albicans</i>: Quorum Sensing or Not Quorum Sensing?. Israel Journal of Chemistry, 2016, 56, 295-301.	1.0	9
26	Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. MBio, 2016, 7, .	1.8	202
27	Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. Infection and Immunity, 2016, 84, 2724-2739.	1.0	144
28	Pathogenesis of<i>Candida albicans</i>biofilm. Pathogens and Disease, 2016, 74, ftw018.	0.8	323
29	Development and <i>In Vivo</i> Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis. Antimicrobial Agents and Chemotherapy, 2016, 60, 881-889.	1.4	39
30	Community-Associated Methicillin-Resistant Staphylococcus aureus: An Enemy amidst Us. PLoS Pathogens, 2016, 12, e1005837.	2.1	80
31	Candida albicans: Love-Hate Relationship with Its Human Host. Microbe Magazine, 2015, 10, 413-418.	0.4	1
32	The Great Escape: Pathogen Versus Host. PLoS Pathogens, 2015, 11, e1004661.	2.1	21
33	Adherence of Streptococcus mutans on lithium disilicate porcelain specimens. Journal of Prosthetic Dentistry, 2015, 114, 696-701.	1.1	22
34	In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. Journal of Antimicrobial Chemotherapy, 2015, 70, 470-478.	1.3	96
35	Clinical Implications of Oral Candidiasis: Host Tissue Damage and Disseminated Bacterial Disease. Infection and Immunity, 2015, 83, 604-613.	1.0	73
36	Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue. Microbiology (United Kingdom), 2015, 161, 168-181.	0.7	209

#	Article	IF	Citations
37	Periodontal Diseases: Bug Induced, Host Promoted. PLoS Pathogens, 2015, 11, e1004952.	2.1	67
38	Microbial cell surface proteins and secreted metabolites involved in multispecies biofilms. Pathogens and Disease, 2014, 70, 219-230.	0.8	32
39	Draft Genome Sequence of the Methicillin-Resistant Staphylococcus aureus Isolate MRSA-M2. Genome Announcements, 2013, 1, .	0.8	18
40	Streptococcus mutans, Candida albicans, and the Human Mouth: A Sticky Situation. PLoS Pathogens, 2013, 9, e1003616.	2.1	236
41	Impaired Histatin-5 Levels and Salivary Antimicrobial Activity against C.albicans in HIV Infected Individuals. Journal of AIDS & Clinical Research, 2013, 04, .	0.5	47
42	Polymicrobial Interactions: Impact on Pathogenesis and Human Disease. Clinical Microbiology Reviews, 2012, 25, 193-213.	5.7	582
43	Staphylococcus aureus adherence to Candida albicans hyphae is mediated by the hyphal adhesin Als3p. Microbiology (United Kingdom), 2012, 158, 2975-2986.	0.7	188
44	Farnesol-Induced Apoptosis in Candida albicans Is Mediated by Cdr1-p Extrusion and Depletion of Intracellular Glutathione. PLoS ONE, 2011, 6, e28830.	1.1	63
45	â€œPersistersâ€ Survival at the Cellular Level. PLoS Pathogens, 2011, 7, e1002121.	2.1	98
46	Pathogenesis of Polymicrobial Biofilms. The Open Mycology Journal, 2011, 5, 39-43.	0.8	27
47	Protection of â€ƒthe oral mucosa by salivary histatin-5 against Candida albicansâ€ƒin an ex vivo murine model of oral infection. FEMS Yeast Research, 2010, 10, no-no.	1.1	23
48	Microbial interactions and differential protein expression in<i>Staphylococcus aureusâ€“Candida albicans</i>dual-species biofilms. FEMS Immunology and Medical Microbiology, 2010, 59, 493-503.	2.7	246
49	Antimicrobial Peptides: Primeval Molecules or Future Drugs?. PLoS Pathogens, 2010, 6, e1001067.	2.1	344
50	A Novel Immune Evasion Strategy of Candida albicans: Proteolytic Cleavage of a Salivary Antimicrobial Peptide. PLoS ONE, 2009, 4, e5039.	1.1	115
51	Farnesol-Induced Apoptosis in <i>Candida albicans</i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 2392-2401.	1.4	210
52	Cross-kingdom interactions:<i>Candida albicans</i>and bacteria. FEMS Microbiology Letters, 2009, 299, 1-8.	0.7	362
53	Farnesol, a Fungal Quorum-Sensing Molecule Triggers Apoptosis in Human Oral Squamous Carcinoma Cells. Neoplasia, 2008, 10, 954-963.	2.3	70
54	Preexisting Oral Disease as a Risk Factor in Oral Complications during PBSCT in Multiple Myeloma Patients. Blood, 2008, 112, 5125-5125.	0.6	0

#	Article	IF	Citations
55	Prevalence of Oral Candida Species in a North American Pediatric Population. Journal of Clinical Pediatric Dentistry, 2007, 31, 260-263.	0.5	14
56	Effect of farnesol onCandida dubliniensisbiofilm formation and fluconazole resistance. FEMS Yeast Research, 2006, 6, 1063-1073.	1.1	105
57	Prevalence of Candida dubliniensis Fungemia at a Large Teaching Hospital. Clinical Infectious Diseases, 2005, 41, 1064-1067.	2.9	51
58	Fungal Biofilms and Drug Resistance. Emerging Infectious Diseases, 2004, 10, 14-19.	2.0	241
59	In vitro studies of the efficacy of antimicrobials against fungi. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2001, 91, 663-670.	1.6	39
60	Evaluation of a Reformulated CHROMagar Candida. Journal of Clinical Microbiology, 2001, 39, 2015-2016.	1.8	45
61	Enhanced Interleukin-1Î², Interleukin-6 and Tumor Necrosis Factor-Î± Production by LPS Stimulated Human Monocytes Isolated from HIV + Patients. Immunopharmacology and Immunotoxicology, 2000, 22, 401-421.	1.1	32
62	Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1999, 88, 573-580.	1.6	59
63	Identification of <i>Candida dubliniensis</i> in a Prospective Study of Patients in the United States. Journal of Clinical Microbiology, 1999, 37, 321-326.	1.8	101
64	Coaggregation of <i>Candida dubliniensis</i> with <i>Fusobacterium nucleatum</i>. Journal of Clinical Microbiology, 1999, 37, 1464-1468.	1.8	74